The Indian government has prohibited the production, sale, and distribution of 16 fixed-dose combination (FDC) drugs citing public health concerns. The Union Health Ministry stated that these medications lack therapeutic justification and pose potential risks to patients.
The move aims to safeguard public health and promote the rational use of medicines. The decision follows a review of FDCs undertaken in compliance with the Supreme Court's directions.
The banned formulations span various therapeutic categories, including dermatological preparations, painkillers, muscle relaxants, and antibiotic-based combinations. Among the prohibited medications are Acetyl Salicylic Acid with Ethoheptazine, Dicyclomine with Paracetamol and Clidinium Bromide, and several antibiotic-based combinations.
The Ministry banned the FDC in notifications issued under Section 26A of the Drugs and Cosmetics Act, 1940. The action is part of the government's efforts to promote the rational use of medicines and strengthen patient safety.
